Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. META
5. NRIX
6. SUNS
7. CRDO
8. OIG
9. SPY
10. SNDX

Go back to Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study

Pfizer (PFE) PT Raised to $30 at Citi

August 13, 2024 4:41 PM EDT

Citi analyst Andrew Baum raised the price target on Pfizer (NYSE: PFE) to $30.00 (from $28.00) while maintaining a Neutral rating.

The analyst comments "We update our forecasts post 2Q24 to incorporate latest results and guidance, and sales, prescription, and currency trends. Our 2024E non-GAAP EPS... More